These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29470212)

  • 1. Risk of Heart-Related Death From Gout Medication.
    Aschenbrenner DS
    Am J Nurs; 2018 Mar; 118(3):23. PubMed ID: 29470212
    [No Abstract]   [Full Text] [Related]  

  • 2. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.
    Jansen TLTA; Janssen M
    Clin Rheumatol; 2019 Jan; 38(1):263-265. PubMed ID: 30542798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febuxostat for the chronic management of hyperuricemia in patients with gout.
    Chinchilla SP; Urionaguena I; Perez-Ruiz F
    Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial.
    Ghang B; Ahn SM; Kim J; Kim YG; Lee CK; Yoo B
    Rheumatology (Oxford); 2020 Jun; 59(6):1439-1440. PubMed ID: 31748801
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gout Medication Receives Black Box Warning.
    Aschenbrenner DS
    Am J Nurs; 2019 Jun; 119(6):24-25. PubMed ID: 31135425
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A word of caution regarding Febuxostat.
    Ochani RK; Yasmin F; Batra S; Asad A
    J Pak Med Assoc; 2019 Dec; 69(12):1930. PubMed ID: 31853136
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
    White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
    N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
    Alten R; Mischkewitz M; Nitschmann S
    Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
    [No Abstract]   [Full Text] [Related]  

  • 11. Underscoring the Importance of Allopurinol in Treating Gout: Results of a Food and Drug Administration-Mandated Safety Trial.
    Nikolov NP; Seymour S; Neuner R; Hsueh YH; Andraca-Carrera E; Mistry K
    Arthritis Rheumatol; 2020 Jun; 72(6):877-878. PubMed ID: 32460423
    [No Abstract]   [Full Text] [Related]  

  • 12. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety update: febuxostat and CVD.
    Drug Ther Bull; 2023 Jul; 61(7):102. PubMed ID: 37321803
    [No Abstract]   [Full Text] [Related]  

  • 14. Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
    Ma KS; Wei JC; Chung WH
    Ann Rheum Dis; 2022 Jun; 81(6):e107. PubMed ID: 32561605
    [No Abstract]   [Full Text] [Related]  

  • 15. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
    Kaul S; Gupta M; Bandyopadhyay D; Hajra A; Deedwania P; Roddy E; Mamas M; Klein A; Lavie CJ; Fonarow GC; Ghosh RK
    Am J Cardiovasc Drugs; 2021 Sep; 21(5):499-512. PubMed ID: 33369719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
    Deng JH; Zhang JX
    Clin Cardiol; 2022 Jul; 45(7):685-686. PubMed ID: 35634752
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hyperuricemia. When and how to treat?].
    Reuss-Borst MA
    Internist (Berl); 2016 Feb; 57(2):194-201. PubMed ID: 26791735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desensitization to febuxostat: report of two cases.
    Di Paolo C; Minetti S; Mineni M; Inverardi S; Rizzini FL; Cinquini M; Tosoni C
    J Allergy Clin Immunol Pract; 2015; 3(4):633-6. PubMed ID: 25758914
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma
    Singh JA
    Ann Rheum Dis; 2022 Jun; 81(6):e108. PubMed ID: 32561599
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.